-
1 Comment
Zhejiang Sunflower Great Health Limited Liability Company is currently in a long term downtrend where the price is trading 4.1% below its 200 day moving average.
From a valuation standpoint, the stock is 5.8% more expensive than other stocks from the Technology sector with a price to sales ratio of 8.5.
Zhejiang Sunflower Great Health Limited Liability Company's total revenue sank by 82.5% to $49M since the same quarter in the previous year.
Its net income has increased by 154.9% to $3M since the same quarter in the previous year.
Finally, its free cash flow grew by 152.6% to $10M since the same quarter in the previous year.
Based on the above factors, Zhejiang Sunflower Great Health Limited Liability Company gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | SHE |
| CurrencyCode | CNY |
| ISIN | CNE100000SX9 |
| PE Ratio | 291.0 |
|---|---|
| Market Cap | 4B |
| Target Price | 15.13 |
| Beta | 0.33 |
| Dividend Yield | None |
Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sale of anti-infectious, cardiovascular, digestive system and other drugs worldwide. It offers clarithromycin API and tablets, an anti-infective drug used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, mycoplasma pneumoniae pneumonia, urethritis and cervicitis, as well as acute pharyngitis and acute tonsillitis; and azithromycin dispersible tablets for sinusitis, acute otitis media, acute bronchitis, acute exacerbation of chronic bronchitis, streptococcus pneumoniae, pneumonia, haemophilus influenzae, mycoplasma pneumoniae, urethritis, cervicitis and skin and soft tissue infection. The company also provides roxithromycin capsules to treat otitis, acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia caused by mycoplasma pneumoniae or chlamydia pneumoniae, urethritis, cervicitis, and skin and soft tissue infection. In addition, it offers lacidipine dispersible tablets for treatment of hypertension; and simvastatin tablets used for pediatric patients, cholesterol, Lipoprotein B, and triglycerides. Further, the company provides omeprazole sodium for injection, a digestive system drug, used as an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; and famotidine for injection for treatment of peptic ulcer bleeding, acute gastric mucosal damage, and gastrointestinal bleeding caused by non-steroidal anti-inflammatory drugs. The company was formerly known as Zhejiang Sunflower Great Health Limited Liability Company and changed its name to Zhejiang Sunflower Great Health Co., Ltd. in December 2023. Zhejiang Sunflower Great Health Co., Ltd. was founded in 2005 and is headquartered in Shaoxing, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300111.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
